Hallucinations during voriconazole therapy

被引：102

作者：

Zonios, Dimitrios I. ^{[1
]}

Gea-Banacloche, Juan ^{[2
]}

Childs, Richard ^{[3
]}

Bennett, John E. ^{[1
]}

机构：

[1] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA

[2] NCI, NIH, Bethesda, MD 20892 USA

[3] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2008年 / 47卷 / 01期

关键词：

D O I：

10.1086/588844

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

As part of a prospective natural history cohort study of voriconazole toxicity, we describe the characteristics of 12 of 72 voriconazole-treated patients who experienced hallucinations from March 2006 through November 2007. Hallucinations associated with voriconazole use are not uncommon. Doctors should be aware of this complication, and the recipients of the drug should be reassured that the hallucinations are an effect of the drug.

引用

页码：E7 / E10

页数：4

共 12 条

[1] Voriconazole-induced musical hallucinations [J].

Agrawal, AK ;

Sherman, LK .

INFECTION, 2004, 32 (05) :293-295

[2] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].

Ally, R ;

Schürmann, D ;

Kreisel, W ;

Carosi, G ;

Aguirrebengoa, K ;

Dupont, B ;

Hodges, M ;

Troke, P ;

Romero, AJ .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454

[3] Adverse reactions to voriconazole [J].

Boyd, AE ;

Modi, S ;

Howard, SJ ;

Moore, CB ;

Keevil, BG ;

Denning, DW .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (08) :1241-1244

[4] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

[5] Adverse effects of voriconazole:: Analysis of the French pharmacovigilance database [J].

Eiden, Celine ;

Peyriere, Helene ;

Cociglio, Marylene ;

Djezzar, Samira ;

Hansel, Sylvie ;

Blayac, Jean-Pierre ;

Hillaire-Buys, Dominique .

ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) :755-763

[6] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[7]

Imhof A, 2006, SWISS MED WKLY, V136, P739

[8] Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial [J].

Kullberg, BJ ;

Sobel, JD ;

Ruhnke, M ;

Pappas, PG ;

Viscoli, C ;

Rex, JH ;

Cleary, JD ;

Rubinstein, E ;

Church, LWP ;

Brown, JM ;

Schlamm, HT ;

Oborska, IT ;

Hilton, F ;

Hodges, MR .

LANCET, 2005, 366 (9495) :1435-1442

[9] Development and validation of a high-performance liquid chromatography assay for voriconazole [J].

Pennick, GJ ;

Clark, M ;

Sutton, DA ;

Rinaldi, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2348-2350

[10]

*PFIZ GLOB RES DEV, 2001, BACKGR DOC ANT DRUG

← 1 2 →